Description

DAILYMET SR 850 MG

Indications

DAILYMET SR 850 MG is primarily indicated for the management of type 2 diabetes mellitus in adults. It is used as an adjunct to diet and exercise to improve glycemic control in patients whose hyperglycemia cannot be managed with diet and exercise alone. Additionally, DAILYMET SR may be prescribed in combination with other antidiabetic medications to enhance therapeutic efficacy.

Mechanism of Action

The active ingredient in DAILYMET SR 850 MG is Metformin hydrochloride, which belongs to the biguanide class of antidiabetic agents. Metformin works primarily by decreasing hepatic glucose production, particularly by reducing gluconeogenesis in the liver. It also enhances insulin sensitivity in peripheral tissues, facilitating increased glucose uptake and utilization. Furthermore, Metformin slows intestinal absorption of glucose, contributing to its overall effect on lowering blood glucose levels.

Pharmacological Properties

Metformin is characterized by its unique pharmacokinetic profile. After oral administration, Metformin is absorbed from the gastrointestinal tract, with peak plasma concentrations occurring approximately 2 to 3 hours post-dose. The bioavailability of Metformin is approximately 50-60% when taken with food, which can influence its absorption. The drug is primarily excreted unchanged in the urine, with a half-life of about 6 hours. Due to its renal clearance, caution is advised in patients with renal impairment, as this can lead to accumulation and increased risk of lactic acidosis.

Contraindications

DAILYMET SR 850 MG is contraindicated in patients with known hypersensitivity to Metformin or any of its components. It should not be used in individuals with severe renal impairment (eGFR < 30 mL/min), acute or chronic metabolic acidosis, including diabetic ketoacidosis, or in patients undergoing procedures requiring the use of iodinated contrast agents. Additionally, it is contraindicated in patients with significant hepatic impairment, as this may increase the risk of lactic acidosis.

Side Effects

The use of DAILYMET SR 850 MG may be associated with several side effects. Common adverse effects include gastrointestinal disturbances such as nausea, vomiting, diarrhea, abdominal discomfort, and flatulence. These symptoms are often transient and may improve with continued use or dose adjustment. Rare but serious side effects include lactic acidosis, particularly in patients with renal insufficiency or other risk factors. Other potential side effects include vitamin B12 deficiency, which may occur with long-term use.

Dosage and Administration

The recommended starting dose of DAILYMET SR 850 MG is typically 850 mg taken orally twice daily, with meals to minimize gastrointestinal side effects. The dosage may be adjusted based on individual patient response and tolerability, with a maximum daily dose not exceeding 2000 mg. It is essential to monitor blood glucose levels regularly to ensure optimal management of diabetes. Patients should be advised to adhere to dietary recommendations and engage in regular physical activity as part of their overall diabetes management plan.

Interactions

DAILYMET SR 850 MG may interact with several medications, which can affect its efficacy or increase the risk of adverse effects. Concomitant use of diuretics, corticosteroids, or other medications that can affect renal function may increase the risk of lactic acidosis. Additionally, the use of alcohol should be minimized, as it can potentiate the effects of Metformin on lactate metabolism. It is crucial for patients to inform their healthcare provider about all medications, supplements, and herbal products they are taking to avoid potential interactions.

Precautions

Patients taking DAILYMET SR 850 MG should be monitored regularly for signs of lactic acidosis, particularly those with risk factors such as renal impairment, dehydration, or concurrent use of other medications that may affect renal function. It is also important to assess renal function periodically, especially in elderly patients or those with comorbid conditions. Patients should be counseled on the importance of adhering to prescribed doses and not to discontinue the medication without consulting their healthcare provider. Additionally, caution should be exercised when considering the use of iodinated contrast media in patients taking Metformin, as this may necessitate temporary discontinuation of the medication.

Clinical Studies

Numerous clinical studies have demonstrated the efficacy and safety of Metformin in the management of type 2 diabetes. A landmark study published in the Diabetes Prevention Program (DPP) showed that Metformin significantly reduced the incidence of diabetes in high-risk individuals by 31% compared to placebo. Furthermore, the UK Prospective Diabetes Study (UKPDS) established that Metformin treatment is associated with a reduction in diabetes-related complications and overall mortality in overweight patients with type 2 diabetes. These studies support the role of Metformin as a first-line therapy in the management of type 2 diabetes and highlight its long-term benefits in glycemic control and weight management.

Conclusion

DAILYMET SR 850 MG is an effective and well-established medication for the management of type 2 diabetes mellitus. Its unique mechanism of action, combined with its favorable safety profile, makes it a cornerstone therapy in diabetes care. However, it is essential for patients to use this medication responsibly, adhere to prescribed dosages, and maintain regular follow-up with their healthcare provider to optimize therapeutic outcomes and minimize potential risks.